At 5.5% CAGR, the SAM Human Papillomavirus (HPV) Vaccine Market is   projected to be worth US$ 239.53 million by 2028, says The Insight  Partners      

According to Business Market Insights’ research, the SAM human papillomavirus (HPV) vaccine market was valued at US$ 173.52 million in 2022 and is expected to reach US$ 239.53 million by 2028, registering an annual growth rate of 5.5% from 2022 to 2028. The advancements in HPV diagnostics tests and initiatives taken by health organizations are the critical factors attributed to the market expansion.        

Healthcare organizations have developed and adopted several strategies to prevent and eliminate HPV infections. The World Health Assembly, in August 2020, adopted the strategy for cervical cancer elimination. As per the strategy, to eliminate cervical cancer, all countries across the region must reach and maintain an incidence rate of below four per 100,000 women. To reduce the incidence rate of cervical cancer, countries should focus on vaccination, screening, and treatment of cervical cancer. In 2016, Gavi Board initiated an HPV vaccine program. That allows countries in their first year of the program to scale up and vaccinate girls between the age of 9 and 14 years. Through this new strategy, Gavi aimed to protect about 40 million girls from cervical cancer by 2020, preventing an estimated 900,000 deaths. Many countries accepted the Gavi support and introduced the HPV vaccine in their national immunization program. Countries with the highest burden of cervical cancer, initiated the Gavi HPV vaccine program. All these initiatives are aiding the HPV vaccines market substantially across the region.

On the contrary, high cost of HPV vaccines hurdles the growth of SAM human papillomavirus (HPV) vaccine market.   

Based on type, the SAM human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment held 62.6% market share in 2022, amassing US$ 108.70 million. It is projected to garner US$ 151.16 million by 2028 to expand at 5.6% CAGR during 2022–2028.    

Based on dosage, the SAM human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment held 84.4% market share in 2022, amassing US$ 146.42 million. It is projected to garner US$ 200.41 million by 2028 to expand at 5.4% CAGR during 2022–2028.     

Based on age, the SAM human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment held 77.5% market share in 2022, amassing US$ 134.54 million. It is projected to garner US$ 187.51 million by 2028 to expand at 5.7% CAGR during 2022–2028.         

Based on application, the SAM human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment held 92.8% market share in 2022, amassing US$ 161.02 million. It is projected to garner US$ 224.24 million by 2028 to expand at 5.7% CAGR during 2022–2028.                

Based on end user, the SAM human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment held 34.1% market share in 2022, amassing US$ 59.10 million. It is projected to garner US$ 79.94 million by 2028 to expand at 5.2% CAGR during 2022–2028.                     

Based on country, the SAM human papillomavirus (HPV) vaccine market has been categorized into Brazil, Argentina, Chile, Guatemala, Peru, Colombia, and rest of SAM.   Our regional analysis states that Brazil captured 26.0% market share in 2022. It was assessed at US$ 45.17 million in 2022 and is likely to hit US$ 61.63 million by 2028, exhibiting a CAGR of 5.3% during the forecast period.                  

Key players dominating the SAM human papillomavirus (HPV) vaccine market are GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; and Serum Institute of India Pvt. Ltd among others.          

• • In May 2022, Serum Institute of India is developing a tetravalent HPV vaccine which includes L1 VLPs of serotypes 6,11,16,18, which is expected to give a coverage of approximately 90% against papilloma virus prevalent in the developing world. The vaccine is currently under development and will be available in the near future.

• • In March 2021, INOVIO announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials (REVEAL 1 and REVEAL 2) evaluating the safety, tolerability and efficacy of VGX-3100 to treat HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL) using the company's proprietary CELLECTRA 5PSP device.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com